Haifa Maalmi1, José Manuel Ordóñez-Mena1, Ben Schöttker1, Hermann Brenner2. 1. German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany. 2. German Cancer Research Center (DKFZ), Division of Clinical Epidemiology and Aging Research, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: h.brenner@dkfz.de.
Abstract
AIM: To estimate the association between serum 25-hydroxyvitamin D (25(OH)D) levels and survival among colorectal and breast cancer patients. METHODS: We performed a comprehensive literature search of prospective cohort studies assessing the association of serum 25(OH)D levels with survival in colorectal and breast cancer patients. Study characteristics and results were extracted and dose-response relationships were graphically displayed in a standardised manner. Meta-analyses using random effects models were performed to estimate pooled hazard ratios. RESULTS: The systematic search yielded five studies including 2330 colorectal cancer patients and five studies including 4413 breast cancer patients all of which compared mortality across two to five categories of 25(OH)D levels. Among colorectal cancer patients, pooled hazard ratios (95% confidence intervals) comparing highest with lowest categories were 0.71 (0.55-0.91) and 0.65 (0.49-0.86) for overall and disease-specific mortality, respectively. For breast cancer patients, the corresponding pooled estimates were 0.62 (0.49-0.78) and 0.58 (0.38-0.84), respectively. No significant evidence of heterogeneity between studies was observed. CONCLUSION: Higher 25(OH)D levels (>75nmol/L) were associated with significantly reduced mortality in patients with colorectal and breast cancer. Randomised controlled trials are needed to evaluate whether vitamin D supplementation can improve survival in colorectal and breast cancer patients with low vitamin D status (25(OH)D<50nmol/L) at diagnosis and before treatment.
AIM: To estimate the association between serum 25-hydroxyvitamin D (25(OH)D) levels and survival among colorectal and breast cancerpatients. METHODS: We performed a comprehensive literature search of prospective cohort studies assessing the association of serum 25(OH)D levels with survival in colorectal and breast cancerpatients. Study characteristics and results were extracted and dose-response relationships were graphically displayed in a standardised manner. Meta-analyses using random effects models were performed to estimate pooled hazard ratios. RESULTS: The systematic search yielded five studies including 2330 colorectal cancerpatients and five studies including 4413 breast cancerpatients all of which compared mortality across two to five categories of 25(OH)D levels. Among colorectal cancerpatients, pooled hazard ratios (95% confidence intervals) comparing highest with lowest categories were 0.71 (0.55-0.91) and 0.65 (0.49-0.86) for overall and disease-specific mortality, respectively. For breast cancerpatients, the corresponding pooled estimates were 0.62 (0.49-0.78) and 0.58 (0.38-0.84), respectively. No significant evidence of heterogeneity between studies was observed. CONCLUSION: Higher 25(OH)D levels (>75nmol/L) were associated with significantly reduced mortality in patients with colorectal and breast cancer. Randomised controlled trials are needed to evaluate whether vitamin D supplementation can improve survival in colorectal and breast cancerpatients with low vitamin D status (25(OH)D<50nmol/L) at diagnosis and before treatment.
Authors: Tsuyoshi Hamada; Li Liu; Jonathan A Nowak; Kosuke Mima; Yin Cao; Kimmie Ng; Tyler S Twombly; Mingyang Song; Seungyoun Jung; Ruoxu Dou; Yohei Masugi; Keisuke Kosumi; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Kana Wu; Katsuhiko Nosho; Kentaro Inamura; Jeffrey A Meyerhardt; Daniel Nevo; Molin Wang; Marios Giannakis; Andrew T Chan; Edward L Giovannucci; Charles S Fuchs; Reiko Nishihara; Xuehong Zhang; Shuji Ogino Journal: Eur J Cancer Date: 2018-09-13 Impact factor: 9.162
Authors: José Manuel Ordóñez-Mena; Ben Schöttker; Veronika Fedirko; Mazda Jenab; Anja Olsen; Jytte Halkjær; Ellen Kampman; Lisette de Groot; Eugene Jansen; H Bas Bueno-de-Mesquita; Petra H Peeters; Galatios Siganos; Tom Wilsgaard; Laura Perna; Bernd Holleczek; Ulrika Pettersson-Kymmer; Philippos Orfanos; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: Eur J Epidemiol Date: 2015-05-15 Impact factor: 8.082
Authors: Stephanie Skender; Jürgen Böhm; Petra Schrotz-King; Jenny Chang-Claude; Erin M Siegel; Karen Steindorf; Robert W Owen; Jennifer Ose; Michael Hoffmeister; Hermann Brenner; Cornelia M Ulrich Journal: Nutr Cancer Date: 2017-01-17 Impact factor: 2.900
Authors: Afsaneh Barzi; Dawn L Hershman; Cathee Till; William E Barlow; Scott Ramsey; Heinz-Josef Lenz; Howard S Hochster; Joseph M Unger Journal: Arch Osteoporos Date: 2019-07-28 Impact factor: 2.617